FDA Issues New Guidance on Promethazine

FDA Issues New Guidance on Promethazine

The Food and Drug Administration (FDA) has recently required labeling changes for promethazine hydrochloride injection products.

The new guidance is intended to further reduce the risk of severe chemical irritation and damage to tissues from intravenous administration of promethazine hydrochloride injection. Do you have injectable promethazine on your formulary? What steps have you taken to protect your patients?

In this week’s client newsletter, we discuss the new promethazine guidance and steps facilities can take to enhance patient safety. If you’re not a client and would like to become one, or if you just need us to point you in the right direction, reach out to us. We’re always happy to hear from you.

The Consultant Pharmacists at OctariusRx provide guidance on safe medication management, survey readiness and cost savings to ambulatory healthcare facilities/surgery centerssenior care facilities and pharmacies. We also help individual patients optimize their medications to improve their quality of life and save money. Contact us for assistance.

Any health, medical or drug information on the Web Site is for informational purposes only. This information is not intended to be used, and you should not use it, as a substitute for obtaining professional healthcare advice, diagnosis or treatment. You should always seek the advice of your doctor, a pharmacist or other qualified healthcare provider for professional healthcare advice, diagnosis or treatment for any medical condition.